DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Xanthine
Xanthine
SCH 58261: a Potent and Selective Non-Xanthine A2A Adenosine Receptor Antagonist
Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness
Pro-Aging Effects of Xanthine Oxidoreductase Products
COPD Agents Review – October 2020 Page 2 | Proprietary Information
(12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
Nouriast Tablets 20 Mg [Non-Proprietary Name] Istradefylline (JAN*) [Applicant] Kyowa Hakko Kirin Co., Ltd
A 1 Adenosine Receptor Agonists and Antiagonists
In-Silico Approaches
Methylxanthines and Neurodegenerative Diseases: an Update
V Olume 51 • Issue 2 • a Ugust 2021
Xanthine (116900) and Oxypurinol (447509) Technical Document
PDL DRUG REVIEW Proprietary Name: Nourianz® Common Name: Istradefylline PDL Category: Anti‐Parkinsonian Drugs
Ehealth DSI [Ehdsi V2.2.1] European Commission
Clinical Applications of Serum Theophylline Measurement by High Pressure Liquid Chromatography
Study Protocol 1
(RAP) Title : Reporting and Analysis Plan for St
Download Product Insert (PDF)
CDR Pharmacoeconomic Review Report for Trelegy Ellipta
Top View
Diccionario Del Sistema De Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS
Adenosine Receptor P1 Receptor
Convergent Evolution of Caffeine in Plants by Co-Option of Exapted Ancestral Enzymes
Curcumin Potentiates 7 Nicotinic Acetylcholine Receptors and Alleviates Autistic-Like Social Deficits and Brain Oxidative Stress
Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol
Unique Role of Caffeine Compared to Other Methylxanthines
Ep 2301628 A1
New Drug Update 2015-16 April 2016
Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development S
Diphylline | Medchemexpress
Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists
Chem. Pharm. Bull. 66(6): 620-623 (2018)
Safety Assessment of Xanthine Alkaloids As Used in Cosmetics
OTHER REVIEW(S) FOOD and DRUG ADMINISTRATION Center for Drug Evaluation and Research Office of Prescription Drug Promotion ****Pre-Decisional Agency Information****
Use of Combinations Comprising a Corticosteroid and a Pyrimidopyrimidine in the Treatment of Inflammatory Diseases
Justification
Methylxanthines Induce Structural and Functional Alterations of the Cardiac
PRODUCT INFORMATION SCH 58261 Item No